Strongbridge Biopharma plc is a biopharmaceutical firm actively engaged in both creating and marketing treatments for rare conditions where patient needs are currently not met. As a commercial-stage entity, its portfolio includes Keveyis, an orally administered carbonic anhydrase inhibitor approved in the United States for addressing hyperkalemic, hypokalemic, and other forms of primary periodic paralysis. The company's development pipeline features several clinical-stage compounds: Recorlev, a cortisol synthesis inhibitor currently undergoing Phase III clinical trials for the management of endogenous Cushing's syndrome, and Veldoreotide, a somatostatin analog, which has successfully completed Phase II clinical trials for acromegaly. Previously known as Cortendo plc, the company rebranded itself as Strongbridge Biopharma plc in September 2015. Established in 1996, Strongbridge Biopharma plc maintains its corporate headquarters in Trevose, Pennsylvania.